Research programme: cancer therapeutics - Debiopharm/EPFLAlternative Names: Debio 0826
Latest Information Update: 18 Apr 2011
At a glance
- Originator Debiopharm
- Developer Debiopharm; Swiss Federal Institute of Technology - Lausanne
- Class Peptides; Small molecules; Venoms
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Apr 2011 Debio 0826 is still in early research for Cancer in Switzerland
- 02 Sep 2008 Early research in Cancer in Switzerland (unspecified route)